are clones of HL-60 and U937 cells latently infected with HIV-1, respectively. PBMCs 114 were obtained from healthy donors and stimulated with phytohaemagglutinin (PHA)
115
(Sigma-Aldrich, Saint Louis, MO). W-3 and KM-3 cells were used for a reporter assay. 
227
Among these, N250 and R259 interact with Tat, and W258 binds to TAR RNA (15).
228
Q172 and F176 do not belong to the TRM, but these amino acids interact with Tat in the inhibitor of HIV-1 replication than C1 and C2 (Fig. 3C ). Its EC 50 was 617 ± 11 nM 244 (Table 1) . C3 also inhibited HIV-1 replication in TNF-α-stimulated U1 cells with an
245
EC 50 of 168 ± 97 nM (Fig. 3D) . C3 reduced the viability of OM-10.1 and U1 cells by 53
246
and 56% of that of the control cells at the concentration of 10,000 nM, respectively (Fig.
247
3C and 3D). The selective index (SI), based on the ratio of 50% cytotoxic concentration
248
(CC 50 ) to EC 50 , was more than 16 and 60 in OM-10.1 and U1 cells, respectively (Table   249 1).
250
In the next experiment, the anti-HIV-1 activity of C3 was examined in CEM cells,
251
MOLT-4 cells, and PBMCs, all of which were acutely infected with HIV-1. As shown in IgG-beads in this assay, the binding level was low. In the presence of C3, the binding of
298
Tat to CycT1 was inhibited by C3 in a dose-dependent fashion, whereas the levels of 299 CDK9 and CycT1 were not affected by the compound (Fig. 7) . These results suggest 300 that C3 specifically targets the interaction between Tat and CycT1. respectively (Fig. 8A ), while they were located on the sites 2, 1, and 3, respectively, in 307 the docking pose 2 (Fig 8B) . When the docking energy of C1−C3 was evaluated in the 308 docking pose 1, the docking energy of C3 was significantly stronger than those of C1
309
and C2 (Fig. 8C) . However, no significant difference of docking energy was observed for cellular functions, the TRM is considered to be a unique interface for Tat-and TAR 330 RNA-binding.
331
As the results of in silico screening followed by in vitro anti-HIV-1 assay, we 
386
In conclusion, the in silico screening system described herein is a useful tool for 387 investigating novel inhibitors that target the TRM of human CycT1, and C3 identified in 388 this system is considered to be a promising lead for novel HIV-1 transcription inhibitors. 
416
All experiments were carried out in duplicate, and mean values are shown. 
